Lai Tsai-Ta

Lai Tsai-Ta is the CEO and co-founder of METiS TechBio, a Beijing-based biotechnology firm. The company is making waves in the longevity market, aiming to reverse or slow the aging process by leveraging artificial intelligence. Lai likens aging to software bugs accumulating in genetic code, suggesting these errors can be "reprogrammed" using AI to read, rewrite, and reverse cellular aging. METiS TechBio recently saw its shares surge 173% on its Hong Kong debut, indicating strong investor interest in AI-driven drug design and longevity solutions. The company's innovative approach, which includes developing "nano-rockets" for drug delivery, positions it as a significant player in the rapidly growing US$610 billion longevity market. Lai's vision and the company's recent market performance highlight the current relevance of AI in tackling fundamental biological processes like aging.